Management Team

Milton H. Werner, Ph.D.
Founder, President & CEO

Prior to founding Inhibikase, Dr. Werner rebuilt research at the cell-free immunotherapeutics company Celtaxsys in Atlanta, Georgia. At Celtaxsys, Dr. Werner drove the research program from the loss of its technology license to a $20 MM pre-money valuation at the opening of the Company’s Series B investment round. Celtaxsys explores the role of proteins in controlling immune cell migration. Previous to Celtaxsys, Dr. Werner was an internationally recognized scientist, Associate Professor and Head of Lab at the Rockefeller University. At the Rockefeller, Dr. Werner focused on elucidating mechanisms of human disease in immunology, oncology and infectious disease.

Dr. Werner received his PhD in Chemistry from the University of California, Berkeley and trained at the National Institutes of Health before joining the Rockefeller in 1996. He is the author of more than 70 research articles, reviews, book chapters and has given lectures on his research work on more than 150 occasions throughout the world. He is recipient of numerous private and public research grants totaling more than $10 million. Dr. Werner is also the recipient of several awards, including the Young Investigator Award from the Sidney Kimmel Cancer Foundation, the Research Chair from the Brain Tumor Society and a $1 million prize from the W. M. Keck Foundation.

Inder Kaul, M.D., M.P.H.
Interim Chief Medical Officer

Inder Kaul, MD, MPH has served as President of Product Development & Chief Medical Officer of Asahi Kasei Pharma America from 2009 until April 2015. From 2006 until 2009, Dr. Kaul served as Vice President, Clinical Development, Medical & Regulatory Affairs of Oscient Pharmaceuticals. From 1998 until 2006, Dr. Kaul served as Division Vice President, Abt Associates Clinical Trials; a division of Abt Associates, Inc. From 1995 to 1998, he served as Vice President, Clinical & Medical Affairs of Medical and Technical Research Associates (later to be known as AAI). Previously Dr. Kaul worked at Searle (now Pfizer) as Medical Director for International Medical Operations where he had responsibilities for all ex-US locations. Prior to Searle, he was the Associate Director Clinical Research (Virology & Immunology) at Boehringer Ingelheim, after having worked as Director Medical Services at Parexel International Corporation. Dr. Kaul started his career in the industry with Candela Laser Corporation in 1988. Dr. Kaul has extensive worldwide research and development leadership experience for multiple therapeutic areas resulting in successful product registrations and post marketing activities. He is proficient in program development as well as project management of INDs, IDEs, NDAs, BLAs, CTDs, PIPs, PSPs, SNDAs, PMAs and 510(k)s. Dr. Kaul received his MD degree in 1983 and a MPH in 1988 from Harvard University.

Martin J. Joyce
Chief Financial Officer

Martin J. Joyce joined Inhibikase as our Chief Financial Officer in December of 2013. Mr. Joyce’s professional background includes leadership roles in public and private, medical device, biotechnology and pharmaceutical companies from start-up stage to over $500 million in annual revenue. He has experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations. Since 2012, Mr. Joyce has served as a consultant to the life science industry assisting biotechnology and pharmaceutical companies in strategic planning, fund raising and operations. From 2011 to 2012, Mr. Joyce was Chief Financial Officer at Lucid Inc., an early stage skin cancer diagnostic company. Previously, Mr. Joyce served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through 2010. He served as BioSphere’s Chief Financial Officer and Vice President from September 2004 to January 2006. From 2001 to 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts.

Terence Kelly, PhD
Medicinal Chemistry Consultant
Mamata Gohlke, PhD, RAC
Voisin Life Science Consulting

Dr. Gokhale is a Regulatory Affairs professional with extensive product development experience in the Pharmaceutical and Biotech industry (12 years) and Regulatory experience at the USFDA (5 years). She has led development programs for small molecules and biologics through all phases of regulatory review.

Previous industry experience includes Manager at Watson Pharmaceuticals, Director at Amgen and Senior Director of Regulatory Affairs and Clinical Development at Neumedicine.

Prabu Nambiar, PhD
Chemistry and Manufacturing Controls and Regulatory

Dr. Nambiar has 20 years of industry experience in the areas of Chemistry, Manufacturing and Controls (CMC) and drug development.  He is regulatory (RAC) certified who has led CMC teams in successful filing of several INDs, NDAs and post approval CMC supplements for  anti-infectives, cardiorenal, neuropharm, gasterointestinal, oncology and pulmonary divisions at FDA and EMA. He is a past CMC Regulatory Director at Cubist and Vice-President at Vertex and the former Head of CMC Regulatory Affairs at AVEO Oncology before founding Syner-G Pharma Consulting, LLC.

Surendra Singh, PhD
Chemistry and Manufacturing Controls

Dr. Singh is an expert Chemical Process Research & Development (Lead Optimization to launch), Technology transfer and API Manufacturing. He was a past Director in Chemical Process Research at Sepracor and Sunovion, and acted as a CMC consultant for AVEO Oncology and RestorGenex and Verastem before joining Syner-G Pharma Consulting, LLC.  For Inhibikase, Dr. Singh manages and establishes commercial process maintenance, global outsourcing, and global vendor management as well as regulatory documents writing/review from IND to NDA.

Roger Rush, PhD
Preclinical Project Management

Dr Rush is a 30 year plus veteran of the pharmaceutical industry working in the United Kingdom and USA for small and large pharmaceutical companies and contract research organizations, and now based in the Greater Boston area. His major career focus has been on preclinical research and development, safety assessment and the translation of discovery research molecules into clinical development. He has contributed to over 20 IND, CTA, product licence submissions, and approved drugs including nicardipine (Cardene), ranolazine (Ranexa), Foscan, and zileuton (Zyflo CR). Most recently he was Vice President Preclinical Development for Idenix Pharmaceuticals where he managed the DMPK, toxicology and discovery research that lead to the identification of lead molecules to treat Hepatitis C virus and the acquisition of the company by Merck & Co. His work has spanned numerous therapeutic areas among them anti-inflammatory and anti-allergy, arthritis, anti-infectives, CNS, cardiovascular, oncology, genitourinary and anti-hyperlipidaemics. He has a B.Sc. and Ph.D. in Biochemistry from the University of Surrey in the United Kingdom

Dan Williams
Controller

Dan acts as the Company’s controller through his own company Startup Personnel, LLC.

Frank McDaniel
Corporate General and Licensing Counsel

Frank McDaniel has acted as the Company’s General Counsel since 2008 and specializes in corporate and transactional law for early stage to mid-size private and publicly traded companies, research institutions and venture capital firms. Frank has substantial expertise within the fields of biotechnology, medical device and other biosciences, healthcare and technology. He has provided legal services to over 40 biotech companies, research institutions and venture capital firms, and been elected to the board of directors for a publicly-traded biotechnology company.

Back to Top